Identification of Fibronectin Type III Domain Containing 3B As a Potential Prognostic and Therapeutic Target for Pancreatic Cancer: a Preliminary Analysis

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Apr 5

PMID 38581008

Authors

Yizhi Wang

Yang Kong

Qifan Yang

Cheng Zhong

Dongkai Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Fibronectin type III domain containing 3B (FNDC3B), a member of the fibronectin type III domain-containing protein family, has been indicated in various malignancies. However, the precise role of FNDC3B in the progression of pancreatic cancer (PC) still remains to be elucidated.

Methods: In this study, we integrated data from the National Center for Biotechnology Information, the Cancer Genome Atlas, Genotype-Tissue Expression database, and Gene Expression Omnibus datasets to analyze FNDC3B expression and its association with various clinicopathological parameters. Subsequently, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes, along with Gene Set Enrichment Analysis (GSEA), single sample Gene Set Enrichment Analysis (ssGSEA) and estimate analysis were recruited to delve into the biological function and immune infiltration based on FNDC3B expression. Additionally, the prognostic estimation was conducted using Cox analysis and Kaplan-Meier analysis. Subsequently, a nomogram was constructed according to the result of Cox analysis to enhance the prognostic ability of FNDC3B. Finally, the preliminary biological function of FNDC3B in PC cells was explored.

Results: The study demonstrated a significantly higher expression of FNDC3B in tumor tissues compared to normal pancreatic tissues, and this expression was significantly associated with various clinicopathological parameters. GSEA revealed the involvement of FNDC3B in biological processes and signaling pathways related to integrin signaling pathway and cell adhesion. Additionally, ssGSEA analysis indicated a positive correlation between FNDC3B expression and infiltration of Th2 cells and neutrophils, while showing a negative correlation with plasmacytoid dendritic cells and Th17 cells infiltration. Kaplan-Meier analysis further supported that high FNDC3B expression in PC patients was linked to shorter overall survival, disease-specific survival, and progression-free interval. However, although univariate analysis demonstrated a significant correlation between FNDC3B expression and prognosis in PC patients, this association did not hold true in multivariate analysis. Finally, our findings highlight the crucial role of FNDC3B expression in regulating proliferation, migration, and invasion abilities of PC cells.

Conclusion: Despite limitations, the findings of this study underscored the potential of FNDC3B as a prognostic biomarker and its pivotal role in driving the progression of PC, particularly in orchestrating immune responses.

References

Li Y, Chen Y, Xu Y, He Q, Yang X, Li Y . FNDC3B 3'-UTR shortening escapes from microRNA-mediated gene repression and promotes nasopharyngeal carcinoma progression. Cancer Sci. 2020; 111(6):1991-2003. PMC: 7293090. DOI: 10.1111/cas.14394. View

Li Y, Meng F, Sui C, Wang Y, Cheng D . CircRNA hsa_circ_0001627 aggravates cervical cancer progression through upregulation of FNDC3B and activating PI3K/mTOR signaling pathway. J Cell Commun Signal. 2022; 17(3):627-638. PMC: 10409949. DOI: 10.1007/s12079-022-00696-w. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Wang Y, Zhou L, Lu J, Jiang B, Liu C, Liang Z . Ubiquitin-specific protease 4 predicts an unfavorable prognosis and promotes malignant behaviors in vitro in pancreatic cancer. Exp Cell Res. 2020; 396(2):112317. DOI: 10.1016/j.yexcr.2020.112317. View

Zhang J, Peng Y, Jiang S, Li J . Hsa_circRNA_0001971 contributes to oral squamous cell carcinoma progression via miR-186-5p/Fibronectin type III domain containing 3B axis. J Clin Lab Anal. 2022; 36(3):e24245. PMC: 8906042. DOI: 10.1002/jcla.24245. View

Li K, Tandurella J, Gai J, Zhu Q, Lim S, Thomas 2nd D . Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 2022; 40(11):1374-1391.e7. PMC: 9669212. DOI: 10.1016/j.ccell.2022.10.001. View

Xia C, Dong X, Li H, Cao M, Sun D, He S . Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022; 135(5):584-590. PMC: 8920425. DOI: 10.1097/CM9.0000000000002108. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Wang Y, Yuan D, Zhou L, Liang Z, Zhou W, Lu J . Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Front Oncol. 2020; 10:576. PMC: 7214815. DOI: 10.3389/fonc.2020.00576. View

10.

Xu H, Hu Y, Qiu W . Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B. Biomed Pharmacother. 2017; 87:405-411. DOI: 10.1016/j.biopha.2016.12.100. View

11.

Bockorny B, Grossman J, Hidalgo M . Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clin Cancer Res. 2022; 28(21):4606-4617. DOI: 10.1158/1078-0432.CCR-21-3452. View

12.

Han B, Wang H, Zhang J, Tian J . FNDC3B is associated with ER stress and poor prognosis in cervical cancer. Oncol Lett. 2020; 19(1):406-414. PMC: 6924122. DOI: 10.3892/ol.2019.11098. View

13.

Chen Y, Yang S, Tavormina J, Tampe D, Zeisberg M, Wang H . Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 2022; 40(8):818-834.e9. PMC: 9831277. DOI: 10.1016/j.ccell.2022.06.011. View

14.

Wang R, Hong K, Zhang Q, Cao J, Huang T, Xiao Z . A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer. Acta Biomater. 2023; 169:451-463. DOI: 10.1016/j.actbio.2023.08.007. View

15.

Qiu J, Feng M, Yang G, Cao Z, Liu Y, You L . mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53LSL-KrasPdx-1-Cre murine models. Cancer Lett. 2022; 554:216020. DOI: 10.1016/j.canlet.2022.216020. View

16.

Boyd L, Ali M, Leeflang M, Treglia G, de Vries R, Le Large T . Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data. EClinicalMedicine. 2022; 55:101747. PMC: 9706531. DOI: 10.1016/j.eclinm.2022.101747. View

17.

Kwon H, Yun M, Kwon T, Bang M, Lee J, Lee Y . Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma. Biomedicines. 2023; 11(12). PMC: 10741045. DOI: 10.3390/biomedicines11123168. View

18.

Ono H, Murase Y, Yamashita H, Kato T, Asano D, Ishikawa Y . RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Int J Oncol. 2023; 62(4). PMC: 10019754. DOI: 10.3892/ijo.2023.5499. View

19.

Papalazarou V, Drew J, Juin A, Spence H, Whitelaw J, Nixon C . Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche. J Cell Sci. 2022; 135(24). PMC: 9845737. DOI: 10.1242/jcs.259978. View

20.

Sieow J, Penny H, Gun S, Tan L, Duan K, Yeong J . Conditional Knockout of Hypoxia-Inducible Factor 1-Alpha in Tumor-Infiltrating Neutrophils Protects against Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2023; 24(1). PMC: 9821271. DOI: 10.3390/ijms24010753. View